Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
50.12(c) 49.94(c) 46.86(c) 46.94(c) 46.06 Last
1 321 908 1 538 575 1 204 946 1 132 090 90 656 Volume
+4.11% -0.36% -6.17% +0.17% -1.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 500 M - -
Net income 2021 16,8 M - -
Net Debt 2021 157 M - -
P/E ratio 2021 391x
Yield 2021 -
Sales 2022 580 M - -
Net income 2022 -60,6 M - -
Net Debt 2022 155 M - -
P/E ratio 2022 -98,1x
Yield 2022 -
Capitalization 5 772 M 5 772 M -
EV / Sales 2021 11,9x
EV / Sales 2022 10,2x
Nbr of Employees 1 700
Free-Float 96,0%
More Financials
Company
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The CompanyÔÇÖs customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The... 
More about the company
Ratings of NeoGenomics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NEOGENOMICS, INC.
09/09NEOGENOMICS' : Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Fur..
PU
09/01NEOGENOMICS : to Participate in the Morgan Stanley 19th Annual Global Healthcare Conferenc..
PU
08/26NEOGENOMICS : Benchmark Capital Adjusts NeoGenomics' Price Target to $50 From $46, Maintai..
MT
08/13INSIDER TRENDS : NeoGenomics Insider Sells for Tax Adds to 90-Day Selling Trend
MT
08/10NEOGENOMICS INC : Regulation FD Disclosure (form 8-K)
AQ
08/09NEOGENOMICS : Morgan Stanley Adjusts Price Target on NeoGenomics to $58 From $64, Maintain..
MT
08/06NEOGENOMICS : Q2 Earnings Snapshot
AQ
08/06NEOGENOMICS : Q2 Net Loss Narrows, Revenue Rises, Reiterates Guidance; Shares Edge Higher ..
MT
08/06NeoGenomics Seeks M&A
CI
08/06NEOGENOMICS INC : Results of Operations and Financial Condition (form 8-K)
AQ
08/06NeoGenomics, Inc. Reiterates Consolidated Earnings Guidance for the Year 2021
CI
08/06NEOGENOMICS : Earnings Flash (NEO) NEOGENOMICS Reports Q2 Loss $-0.01
MT
08/06NEOGENOMICS : Earnings Flash (NEO) NEOGENOMICS Reports Q2 Revenue $121.7M
MT
08/06GUIDANCE : (NEO) NEOGENOMICS Forecasts Fiscal Year 2021 Revenue Range $490M - $510M
MT
08/06NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
News in other languages on NEOGENOMICS, INC.
09/27PANAKES PARTNERS : Rob Woodman a capo degli investimenti biotech
01/04Quels ETF choisir pour investir dans les valeurs moyennes ?
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 46,94 $
Average target price 56,80 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Douglas M. Van Oort Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors